Autosis is a recently characterized form of non-apoptotic cell death that was first described in 2016. It is a unique type of programmed cell death that is distinct from apoptosis, necrosis, ferroptosis, and other known cell death pathways. The name "autosis" derives from "auto-" (self) and "-osis" (process), reflecting its characteristic of self-degradation.
Autosis is morphologically and mechanistically distinct from other forms of cell death. It is characterized by:
This cell death pathway has been implicated in several neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and ischemic brain injury.
| Molecule | Function | Role in Autosis |
|---|---|---|
| Na+/K+ ATPase | Ion pump maintaining gradients | Inhibition triggers autosis |
| Cathepsin L | Lysosomal protease | Mediates protein degradation |
| Cathepsin B | Lysosomal protease | Contributes to cell death |
| ATG proteins | Autophagy machinery | Required for autophagosome formation |
| mTOR | Nutrient sensor | Inhibition promotes autosis |
| AMPK | Energy sensor | Activation can induce autosis |
| Feature | Autosis | Apoptosis | Ferroptosis | Necroptosis |
|---|---|---|---|---|
| Morphology | Swollen, enlarged autophagic vacuoles | Cell shrinkage, chromatin condensation | Cell shrinkage, iron accumulation | Cell swelling, membrane rupture |
| Nuclear changes | Indented, intact | Fragmented, condensed | Intact | Intact |
| Energy requirement | Yes (ATP-dependent early) | Yes (caspase-dependent) | No | No |
| Autophagy involvement | Excessive, pathogenic | Not involved | Can contribute | Not involved |
| Inhibitors | Nicotinamide, ouabain | Caspase inhibitors | Ferrostatin-1 | Necrostatin-1 |
In PD models, autosis has been observed in:
The mechanism involves:
Autosis contributes to neuronal loss in AD through:
Neuronal autosis in AD shows distinctive features:
Autosis is a significant contributor to neuronal death following cerebral ischemia:
Motor neuron death in ALS may involve autosis:
| Compound | Mechanism | Therapeutic Potential |
|---|---|---|
| Nicotinamide | Inhibits autophagic flux | Neuroprotective in PD models |
| Ouabain | Na+/K+ ATPase activator | Blocks autosis initiation |
| Cathepsin inhibitors | Blocks cathepsin activity | Potential therapeutic |
| 3-MA | Inhibits autophagy initiation | Prevents autosis |
Related pathways and pages:
The study of Autosis Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 8 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |
Overall Confidence: 36%